Identity, Handling, And Regulation — What the Evidence Shows

By Editorial Desk · published 2026-07-21 · last reviewed 2026-08-01 · Info

This is a working overview of Stenabolic, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

Identity, Handling, and Regulation

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Analytical Detection and Stability

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Sr9009 at a glance

Background and Mechanism of SR9009

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Related pages on this site

• Optimized briefing
• Practical summary
• Focused guide
• Standard toolkit
• Efficient handbook
• Simple trends
• Efficient workbook
• Measured dataset

SR9009 Background and Receptor Mechanism

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

SR9009 Identity and Mechanism

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

Background from the literature

Sanyaa – a type of dried fish prepared by the Newars. Dried shrimp – shrimp that have been sun-dried and shrunk. They are used in many Asian cuisines, imparting a unique umami taste. Shũṭki (শুঁটকি) or Shũṭki machh (শুঁটকি মাছ) – sun-dried fish or shrimp as prepared in Bengali and Assamese cuisine in India and Bangladeshi cuisine in general. In Western India it's colloquially called Bombay Duck. Dried fish is also used in some parts of South India and Sri Lanka Dried shredded squid – a dried, seasoned, seafood product, made from squid or cuttlefish, commonly found in coastal Asian countries, Russia, and Hawaii. Stockfish – unsalted fish, especially cod, dried by cold air and wind on wooden racks on the foreshore, called "hjell".

In humans, excessive exposure to UV radiation can result in acute and chronic harmful effects on the eye's dioptric system and retina. The risk is elevated at high altitudes and people living in high latitude areas where snow covers the ground right into early summer and sun positions even at zenith are low, are particularly at risk. Skin, the circadian system, and the immune system can also be affected. The differential effects of various wavelengths of light on the human cornea and skin are sometimes called the "erythemal action spectrum". The action spectrum shows that UVA does not cause immediate reaction, but rather UV begins to cause photokeratitis and skin redness (with lighter skinned individuals being more sensitive) at wavelengths starting near the beginning of the UVB band at 315 nm, and rapidly increasing to 300 nm. The skin and eyes are most sensitive to damage by UV at 265–275 nm, which is in the lower UVC band. At still shorter wavelengths of UV, damage continues to happen, but the overt effects are not as great with so little penetrating the atmosphere. The WHO-standard ultraviolet index is a widely publicized measurement of total strength of UV wavelengths that cause sunburn on human skin, by weighting UV exposure for action spectrum effects at a given time and location. This standard shows that most sunburn happens due to UV at wavelengths near the boundary of the UVA and UVB bands.

In 1897, John Jacob Abel (1857–1938) of Johns Hopkins University, the first chairman of the first US department of pharmacology, found a compound called epinephrine with the molecular formula of C17H15NO4. Abel claimed his principle from adrenal gland extract was active. In 1900, Jōkichi Takamine (1854–1922), a Japanese chemist, worked with his assistant, Keizo Uenaka (1876–1960), to purify a 2000 times more active principle than epinephrine from the adrenal gland, named adrenaline with the molecular formula C10H15NO3. Additionally, in 1900 Thomas Aldrich of Parke-Davis Scientific Laboratory also purified adrenaline independently. Takamine and Parke-Davis later in 1901 both got the patent for adrenaline. The fight for terminology between adrenaline and epinephrine was not ended until the first adrenaline structural discovery by Hermann Pauly (1870–1950) in 1903 and the first adrenaline synthesis by Friedrich Stolz (1860–1936), a German chemist in 1904. They both believed that Takamine's compound was the active principle while Abel's compound was the inactive one. Stolz synthesized adrenaline from its ketone form (adrenalone).

=== Carbohydrate layer === After synthesizing and purifying the core, the carbohydrate layer is added to its surface. Common coating materials are typically polyhydroxy oligomers such as cellobiose, citrate, lactose, and sucrose. This layer seems to be important for the properties of aquasomes, as it influences several drug characteristics including adsorption, molecular stability, and conformation (shape), and acts as a dehydroprotectant. The addition of the carbohydrate layer to the surface of the nanocrystalline core is commonly carried out by passive adsorption through incubation and sonication. Similar to the processing of the core, the carbohydrate layer is subjected to centrifugation, washing, and further sonification followed by heated air drying.

Sources: en.wikipedia.org

Reference notes

All major powers engaged in espionage, using a great variety of spies, double agents, moles, and new technologies such as the tapping of telephone cables. The Soviet KGB ("Committee for State Security"), the bureau responsible for foreign espionage and internal surveillance, was famous for its effectiveness. The most famous Soviet operation involved its atomic spies that delivered crucial information from the United States' Manhattan Project, leading the USSR to detonate its first nuclear weapon in 1949, four years after the American detonation and much sooner than expected. A massive network of informants throughout the Soviet Union was used to monitor dissent from official Soviet politics and morals. Although to an extent disinformation had always existed, the term itself was invented, and the strategy formalized by a black propaganda department of the Soviet KGB. Based on the amount of top-secret Cold War archival information that has been released, historian Raymond L. Garthoff concludes there probably was parity in the quantity and quality of secret information obtained by each side. However, the Soviets probably had an advantage in terms of HUMINT (human intelligence or interpersonal espionage) and "sometimes in its reach into high policy circles." In terms of decisive impact, however, he concludes:

== Bioart == Gibson gave a talk to the International Society for Anthrozoology (ISAZ) at Cambridge University in July 2012 about the use of live insects in art and entertainment. On 8 February 2017 Gibson walked naked in front of the Vancouver Law Courts in the middle of winter to protest Canada's ban of genetic engineering of the human genome. He walked nude in downtown Vancouver for 11 minutes, 45.75 seconds in a light rain and a temperature of 7 degrees Celsius (45 °F).

In modern Europe and North America, ayahuasca analogues (i.e., variants) are often prepared using non-traditional plants which contain the same alkaloids. For example, seeds of the Syrian rue plant can be used as a substitute for the ayahuasca vine, and the DMT-rich Mimosa hostilis is used in place of chacruna. Australia has several indigenous plants which are popular among modern ayahuasqueros there, such as various DMT-rich species of Acacia. The name "ayahuasca" specifically refers to a decoction that contains Banisteriopsis caapi. Brews similar to ayahuasca may be prepared using several plants not traditionally used in South America: DMT admixtures:

Sources: en.wikipedia.org

Notes from published material

== SH == SH (s) Saint Helena (ISO 3166 digram) (p) SONATRACH (Algerian petroleum company) Shanghai SHAC (a) Stop Huntingdon Animal Cruelty SHAPE – (a) Supreme Headquarters Allied Powers Europe SHF – (i) Super High Frequency SHN – (s) Saint Helena (ISO 3166 trigram) SHO – (a) Showtime (see also sho.com) SHOALS – (a) Scanning Hydrographic Operational Airborne Lidar Survey SHORAD – (p) Short Range Air Defence SHORADEZ – (p) SHORAD Engagement Zone SHP – (s) Saint Helena pound (ISO 4217 currency code) SHRA – (s) Rain Showers (METAR Code) SHSN – (s) Snow Showers (METAR Code)

The secretary of the British Red Cross, Percy Lane Oliver, established the world's first blood-donor service in 1921. In that year, Oliver was contacted by King's College Hospital, where they were in urgent need of a blood donor. After providing a donor, Oliver set about organizing a system for the voluntary registration of blood donors at clinics around London, with Sir Geoffrey Keynes appointed as a medical adviser. Volunteers were subjected to a series of physical tests to establish their blood group. The London Blood Transfusion Service was free of charge and expanded rapidly in its first few years of operation. By 1925 it was providing services for almost 500 patients; it was incorporated into the structure of the British Red Cross in 1926. Similar systems developed in other cities, including Sheffield, Manchester and Norwich, and the service's work began to attract international attention. France, Germany, Austria, Belgium, Australia and Japan established similar services. Alexander Bogdanov founded an academic institution devoted to the science of blood transfusion in Moscow in 1925. Bogdanov was motivated, at least in part, by a search for eternal youth, and remarked with satisfaction on the improvement of his eyesight, suspension of balding, and other positive symptoms after receiving 11 transfusions of whole blood. Bogdanov died in 1928 as a result of one of his experiments, when the blood of a student with malaria and tuberculosis was given to him in a transfusion.

Duchenne muscular dystrophy (DMD) is a severe type of muscular dystrophy predominantly affecting males. The onset of muscle weakness typically begins around age four, with rapid progression. Initially, muscle loss occurs in the thighs and pelvis, extending to the arms, which can lead to difficulties in standing up. By the age of 12, most individuals with Duchenne muscular dystrophy are unable to walk. Affected muscles may appear larger due to an increase in fat content, and scoliosis is common. Some individuals may experience intellectual disability, and females carrying a single copy of the mutated gene may show mild symptoms. Duchenne muscular dystrophy is caused by mutations or deletions in any of the 79 exons encoding the large dystrophin protein, which is essential for maintaining the muscle fibers' cell membrane integrity. The disorder follows an X-linked recessive inheritance pattern, with approximately two-thirds of cases inherited from the mother and one-third resulting from a new mutation. Diagnosis can frequently be made at birth through genetic testing, and elevated creatine kinase levels in the blood are indicative of the condition. While there is no known cure, management strategies such as physical therapy, braces, and corrective surgery may alleviate symptoms. Assisted ventilation may be required in those with weakness of breathing muscles. Several drugs designed to address the root cause are currently available including gene therapy (Elevidys), and antisense drugs (Ataluren, Eteplirsen etc.).

The CAP has three main parts. First, the European Agricultural Guarantee Fund distributes 'direct payments', which are 70.9% of the CAP budget. The Direct Payments Regulation 2013 gives payments to an 'active farmer' that carries out agricultural activity, grazing or cultivation, does not operate airports, rail, waterworks, real estate, sport or recreation grounds, and has the land at their disposal. The farm must have at least 1 hectare and receive €100 for each, though member states can set higher thresholds (e.g. 5 hectares and €200). If payments reach over €150,000 there is a 5% reduction per hectare for each hectare. This favours large farm corporations, and the largest 1% typically receive around 10 to 15% of all subsidies in member states. As conditions of receiving subsidies, farms can be required to keep land in good condition, for public, animal, and plant health, and maintain environment standards. For minimal biodiversity, farmers must have over two crops if they have 10 hectares, not farm at least 5% of lintensively (an 'ecological focus area' over 15 hectares, and have three crops over 30 hectares. Environmentally sensitive grasslands, as designated by the Habitats Directive 1992 and the Wild Birds Directive 2009, should not be more turned into more than 5% agricultural area. The second main part, also carried out by the EAGF, is 'market measures'. Under the Agricultural Products Regulation 2013 certain crops and meat are eligible for purchase by member state authorities, to be 'stored by them until disposed of', with extra aid for storage.

Sources: en.wikipedia.org

Frequently asked questions